AU2017301949B2 - Compounds, reagents, and uses thereof - Google Patents

Compounds, reagents, and uses thereof Download PDF

Info

Publication number
AU2017301949B2
AU2017301949B2 AU2017301949A AU2017301949A AU2017301949B2 AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2 AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2
Authority
AU
Australia
Prior art keywords
compound
subject
level
salt
kidney function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017301949A
Other languages
English (en)
Other versions
AU2017301949A1 (en
Inventor
Anne M. Evans
Qibo Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of AU2017301949A1 publication Critical patent/AU2017301949A1/en
Application granted granted Critical
Publication of AU2017301949B2 publication Critical patent/AU2017301949B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2017301949A 2016-07-28 2017-07-27 Compounds, reagents, and uses thereof Active AU2017301949B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367839P 2016-07-28 2016-07-28
US62/367,839 2016-07-28
PCT/US2017/044151 WO2018022866A1 (en) 2016-07-28 2017-07-27 Diagnostic methods, therapeutic agents and uses thereof

Publications (2)

Publication Number Publication Date
AU2017301949A1 AU2017301949A1 (en) 2019-01-31
AU2017301949B2 true AU2017301949B2 (en) 2021-09-23

Family

ID=59579921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017301949A Active AU2017301949B2 (en) 2016-07-28 2017-07-27 Compounds, reagents, and uses thereof

Country Status (8)

Country Link
US (1) US10865183B2 (enExample)
EP (1) EP3491004B1 (enExample)
JP (1) JP6987123B2 (enExample)
CN (1) CN109563127B (enExample)
AU (1) AU2017301949B2 (enExample)
CA (1) CA3032116A1 (enExample)
ES (1) ES2891088T3 (enExample)
WO (1) WO2018022866A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391220B (es) * 2013-05-14 2025-03-21 Metabolon Inc Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
US11182920B2 (en) * 2018-04-26 2021-11-23 Jerry NAM Automated determination of muscle mass from images
TWI669506B (zh) * 2018-07-06 2019-08-21 國軍桃園總醫院 計算腎絲球過濾率之方法
CN114829940A (zh) * 2019-12-16 2022-07-29 希尔氏宠物营养品公司 用于诊断和治疗肾病的方法、试剂盒和组合物
WO2021232211A1 (zh) * 2020-05-19 2021-11-25 深圳市中医院 诊断肾病的标志物以及诊断方法
CN119355249A (zh) * 2024-09-20 2025-01-24 长沙都正生物科技股份有限公司 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186311A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
WO2015087985A1 (ja) * 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186311A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
WO2015087985A1 (ja) * 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROBERT G. FASSETT ET AL, "Biomarkers in chronic kidney disease: a review", KIDNEY INTERNATIONAL, (2011-10-01), vol. 80, no. 8, pages 806 - 821 *
SABINE GEBAUER ET AL, "Three-Dimensional Quantitative Structure-Activity Relationship Analyses of Peptide Substrates of the Mammalian H + /Peptide Cotransporter PEPT1", J. Med Chem, (2003-12-01), vol. 46, no. 26, pages 5725 - 5734 *
W L Mock ET AL, "Specificity and pH dependence for acylproline cleavage by prolidase", Journal of Biological Chemistry, (1990-11-15), pages 19600 - 19605 *

Also Published As

Publication number Publication date
JP2019531261A (ja) 2019-10-31
CA3032116A1 (en) 2018-02-01
JP6987123B2 (ja) 2021-12-22
WO2018022866A1 (en) 2018-02-01
CN109563127A (zh) 2019-04-02
EP3491004B1 (en) 2021-09-01
ES2891088T3 (es) 2022-01-26
US10865183B2 (en) 2020-12-15
AU2017301949A1 (en) 2019-01-31
US20190152907A1 (en) 2019-05-23
EP3491004A1 (en) 2019-06-05
CN109563127B (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
AU2017301949B2 (en) Compounds, reagents, and uses thereof
US20210116467A1 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
US12055535B2 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
JP2022091763A (ja) 肝疾患関連バイオマーカーおよびその使用方法
CA2775033C (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
US20200110069A1 (en) Diagnostic methods, therapeutic agents and uses thereof
US20230091848A1 (en) Disease detection and treatment based on phenylacetyl glutamine levels
US11680042B2 (en) Compounds, reagents, and uses thereof
WO2019097089A1 (en) Methods for prediction and early detection of diabetes
WO2012007531A2 (en) Methods and compositions for diagnosing medical conditions
US20160195550A1 (en) Metabolism of sod1 in csf
JP7169594B2 (ja) 糖尿病合併症用マーカー

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS, REAGENTS, AND USES THEREOF

FGA Letters patent sealed or granted (standard patent)